3 AI Stocks Revolutionizing Traditional Trillion-Dollar Industries

Key Points

• Palantir’s AI platform delivers 46% operating margins while being deeply integrated into government operations, creating a formidable competitive advantage that would take competitors decades to replicate.

• Recursion’s AI-powered biological data platform (65+ petabytes) accelerates drug discovery from years to weeks, with validation through partnerships with pharmaceutical giants like Roche and Sanofi.

• JPMorgan Chase processes 65 million AI transactions daily while trading at just 16 times earnings, leveraging an $18 billion tech budget that surpasses most fintech competitors combined.

The most compelling AI investment opportunities aren’t found among the headline-grabbing tech darlings. Instead, they’re emerging within established trillion-dollar industries that have remained largely unchanged for decades—until now.

Defense, pharmaceuticals, banking, and healthcare represent massive global economic pillars now facing AI-driven disruption. Companies leading this transformation are building competitive advantages so substantial that even Silicon Valley’s giants struggle to compete.

These three stocks transcend simple AI investments—they’re pioneering fundamental transformations in mission-critical industries. Here’s why they deserve consideration for long-term investment portfolios.

The Defense Intelligence Innovator

Palantir Technologies (NASDAQ: PLTR) spent two decades becoming indispensable to intelligence agencies before catching Wall Street’s attention. Now, its Artificial Intelligence Platform (AIP) is delivering for corporations what its Gotham platform did for governments—transforming chaos into actionable intelligence.

Q2 2025 revenue reached $1 billion, up 48% year over year, with U.S. commercial revenue surging 93% to $306 million. Over 1,000 organizations are running AIP pilots, from Airbus optimizing supply chains to hospitals predicting patient capacity needs.

While a 243x forward earnings multiple appears steep, Palantir’s financial foundation is robust—46% operating margins, $6 billion in cash and short-term securities, and raised full-year 2025 guidance to $4.14-4.15 billion. The company’s true competitive advantage extends beyond technology to decades of security clearances, deep Pentagon integration, and institutional knowledge that competitors would need 20+ years to replicate. When military targeting operations depend on your software, switching providers isn’t realistic.

Web3 Perspective: Palantir’s data analytics capabilities have significant potential in the blockchain intelligence sector. The company’s experience handling sensitive government data positions it uniquely to develop advanced solutions for blockchain transaction monitoring, fraud detection, and security—crucial infrastructure elements as institutional adoption of digital assets continues to accelerate.

The AI-Powered Drug Discovery Pioneer

Recursion Pharmaceuticals (NASDAQ: RXRX) is industrializing drug discovery through artificial intelligence. The company has built one of Earth’s largest proprietary biological datasets—over 65 petabytes—feeding AI models that identify promising drug candidates in weeks rather than years. Partnerships with pharmaceutical leaders including Roche, Bayer, Sanofi, and Nvidia validate this approach, with Sanofi alone contributing $130 million in upfront and milestone payments to date.

Q2 2025 revenue reached $19.2 million, up 33% year over year, placing the company on a $77 million annual run rate. However, current revenue isn’t the appropriate metric for evaluating a pre-commercial biotech company. More meaningful indicators include five programs in clinical trials, ten approaching human studies, and an AI platform capable of generating drug candidates exponentially faster than traditional methods. Should even one AI-discovered compound achieve blockbuster status, today’s valuation would represent merely a fraction of its potential value.

Web3 Perspective: Recursion’s computational approach to drug discovery parallels developments in decentralized science (DeSci) projects in the Web3 space. The company could potentially leverage blockchain technology for secure, transparent management of its vast datasets, while tokenization models could create new research funding mechanisms and incentive structures for distributed computational resources—opening new frontiers in collaborative drug development.

The AI Banking Powerhouse

JPMorgan Chase (NYSE: JPM) isn’t simply the world’s largest bank by assets—it’s transforming into the blueprint for AI implementation in finance. The institution processes over 65 million AI-powered transactions daily, spanning fraud detection, algorithmic trading, and risk assessment. Its annual technology budget of $18 billion dwarfs most fintech companies combined, yielding tangible results: AI systems prevented $1.5 billion in fraud losses last year, while new underwriting algorithms now approve loans in seconds instead of days.

The bank is also advancing up the value chain. Its IndexGPT generative AI advisor automates tasks traditionally handled by junior wealth managers. In institutional banking, AI systems are reshaping risk management and capital allocation at unprecedented scale. Q2 2025 earnings demonstrated the institution’s financial power: $15 billion in net income on $45.7 billion in revenue.

At just 16 times forward earnings, JPMorgan trades significantly below the S&P 500’s 22 times multiple, despite its position as the world’s most systemically important financial institution. Its massive deposit base, regulatory licenses, and global infrastructure present barriers no challenger bank can easily overcome. CEO Jamie Dimon has called AI “extraordinary and groundbreaking”—and is restructuring the entire organization around this technology revolution.

Web3 Perspective: JPMorgan’s blockchain unit Onyx demonstrates its commitment to digital asset innovation alongside AI development. The bank’s private blockchain network handles over $1 trillion in daily transactions, positioning it uniquely to bridge traditional finance with emerging digital asset ecosystems. As regulatory frameworks evolve, JPMorgan’s dual expertise in AI and blockchain technology creates competitive advantages that pure-play fintech companies struggle to match.

These three companies represent more than just AI investments—they’re reshaping fundamental industries through technological transformation. Their established market positions, proprietary data advantages, and integration into critical infrastructure create investment opportunities as AI disruption accelerates across traditional economic sectors.